Clinical Trials Logo

Leukopenia clinical trials

View clinical trials related to Leukopenia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06360952 Not yet recruiting - Neutropenia Clinical Trials

A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC

Start date: May 31, 2024
Phase:
Study type: Observational

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders. This investigation will include a minimum of 40 sample sets from unique patients.

NCT ID: NCT06285825 Not yet recruiting - Cytopenia Clinical Trials

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Start date: July 31, 2024
Phase: Early Phase 1
Study type: Interventional

To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.

NCT ID: NCT06240754 Not yet recruiting - Clinical trials for Clonal Cytopenia of Undetermined Significance

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

NCT ID: NCT00243165 Not yet recruiting - Breast Cancer Clinical Trials

Lifemel Honey to Reduce Leucopenia During Chemotherapy

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.